Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04053543
Recruitment Status : Recruiting
First Posted : August 12, 2019
Last Update Posted : November 26, 2019
Sponsor:
Collaborators:
Medpace, Inc.
Innovative Analytics
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Information provided by (Responsible Party):
Complexa, Inc.

Brief Summary:
This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.

Condition or disease Intervention/treatment Phase
PAH Drug: CXA-10 Phase 2

Detailed Description:

This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.

The study will be performed in approximately 50 study centers across the United States and the United Kingdom, which participated in CXA-10-301. Approximately 96 subjects who completed treatment in CXA-10-301 will be eligible to participate in this OLE study, after completing all Visit 9 (Day 1 and Day 2) assessments in CXA-10-301.

Study participation for each subject will last up to approximately 6.5 months. The study will consist of a 6 month open-label treatment period and require 5 clinic visits and 1 telephone visit, including the Baseline Visit completed simultaneously with Visit 9 CXA-10-301, plus a follow-up visit approximately 2 weeks following the last dose of CXA-10.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Intervention Model: Single Group Assignment
Intervention Model Description: CXA-10
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301
Actual Study Start Date : August 9, 2019
Estimated Primary Completion Date : February 28, 2021
Estimated Study Completion Date : February 28, 2021


Arm Intervention/treatment
Experimental: 150mg CXA-10
Once daily dosing of 150mg CXA-10 in the morning
Drug: CXA-10
(10-nitro-9(E)-octadec-9enoic acid)




Primary Outcome Measures :
  1. Incidence of AEs [ Time Frame: 6 months ]
    Adverse events occurring during the treatment period

  2. Changes in respiration [ Time Frame: 6 months ]
    Change from baseline values at each post-baseline time point

  3. Changes in heart rate [ Time Frame: 6 months ]
    Change from baseline values at each post-baseline time point

  4. Changes in blood pressure [ Time Frame: 6 months ]
    Change from baseline values at each post-baseline time point


Secondary Outcome Measures :
  1. PAH-specific medication changes [ Time Frame: 6 months ]
    Addition or removal of PAH-specific medications, including any dose changes

  2. 6 Minute Walk Distance [ Time Frame: 6 months ]
    Change from baseline in 6-minute walk distance (6MWD)

  3. Who Classification of Functional Status [ Time Frame: 6 months ]
    Change from baseline in WHO Classification of Functional Status of Patients with PH

  4. Clinical worsening [ Time Frame: 6 months ]
    Death from any cause, hospitalization for worsening PAH, Disease progression, unsatisfactory long-term clinical response



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document indicating subject has been informed of all pertinent aspects of the study prior to initiation of any study-required procedures.
  2. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
  3. Has completed the CXA-10-301 study and demonstrated compliance with study medication administration and study requirements.
  4. If receiving simvastatin-containing products: simvastatin (Zocor), Vytorin, or any other combination therapy containing simvastatin, simvastatin dose does not exceed 20 mg/day.
  5. Currently receiving no more than three of the following previously approved PAH therapies: phosphodiesterase type 5 (PDE-5) inhibitors, endothelin receptor antagonists (ERA), soluble guanylate cyclase (sGC) stimulator, prostanoids, prostacyclin receptor agonists.
  6. Women of childbearing potential and males with partners of childbearing potential must agree to use a reliable method of contraception while taking study medication.

Exclusion Criteria:

  1. Severe hypotension defined by systolic blood pressure <90 mmHg from sitting blood pressure measurement at Baseline.
  2. Hypertensive defined by >160 mmHg systolic or >110 mmHg diastolic from sitting blood pressure measurement at Baseline.
  3. QTcF on supine ECGs at Baseline (Visit 1) of >500 msec.
  4. Acute myocardial infarction or acute coronary syndrome (ST-Elevation Myocardial Infarction [STEMI], Non STEMI [NSTEMI] and or unstable angina) within the last 90 days prior to Baseline.
  5. Recent cerebrovascular accident/transient ischemic attack (CVA/TIA) within the last 90 days prior to Baseline.
  6. Recent hospitalization for left heart failure within the last 90 days prior to Baseline.
  7. Clinically significant aortic or mitral valve disease defined as greater than mild regurgitation or mild stenosis; pericardial constriction; restrictive or constrictive cardiomyopathy; left ventricular dysfunction (LVEF < 50%); left ventricular outflow obstruction; symptomatic coronary artery disease; autonomic hypotension; or fluid depletion, in the opinion of the investigator.
  8. Chronic atrial fibrillation and life-threatening cardiac arrhythmias.
  9. Personal or family history of congenital prolonged QTc syndrome or sudden unexpected death due to a cardiac reason.
  10. Clinically significant anemia in the opinion of the investigator that precludes enrollment into this study, or Hb <9 gm/dl.
  11. Severe hepatic impairment (Child-Pugh class C with or without cirrhosis) at Baseline or active chronic hepatitis.
  12. Received intravenous inotropes within 2 weeks prior to Baseline (e.g. dopamine, dobutamine).
  13. History of angina pectoris or other condition that was treated with long or short acting nitrates <12 weeks of Baseline.
  14. History of herbal or natural medication use (including fish oil) within 2 weeks or 5 half-lives, whichever is longer, prior to Baseline.
  15. Received prednisone at doses > 15 mg/ day or changes in immunosuppressive medications <12 weeks prior to Baseline.
  16. Currently taking a drug that may affect the assay measurement of serum creatinine (e.g. cimetidine, Bactrim, Pyridium). A list is provided in Appendix H.

21. Newly prescribed drug or increased dose of an existing drug that is known to prolong the QTc interval and has been associated with Torsades de Pointes (TdP) identified in the CredibleMeds.org website list as known risk (KR) of TdP.

Note: Stable doses of drugs classified as conditional risk (CR) of TdP or possible risk (PR) of TdP are permitted (i.e., subject has received the same dose and regimen for at least 30 days prior to Baseline with no anticipated changes to the dose or regimen during the course of the study).

22. Currently taking dimethyl fumarate (Tecfidera™).

23. Any of the following laboratories abnormal and unresolved in CXA-10-301:

  1. Absolute lymphocyte counts < 0.5 x 109 cells/L.
  2. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3.0X upper limit of normal (ULN), alkaline phosphatase (AP) > 2X ULN of liver origin, and total bilirubin >2X ULN. If all liver function tests (LFTs) are within normal limits (WNL) and total bilirubin is elevated, examination of direct and indirect bilirubin may be conducted to evaluate for Rotor's/Gilbert's Syndrome. Subjects with Rotor's/Gilbert's Syndrome may be enrolled.
  3. eGFR < 30 mL/min/1.73 m2 (estimated by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] Creatinine/Cystatin C 2012 algorithm) at Baseline.

    24. Females who are pregnant or breastfeeding, or who are trying to conceive. 25. Recent (within 1 year) history of abusing alcohol or illicit drugs. 26. History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, or other malignancies (such as thyroid or testicular) that have been curatively treated and with no evidence of disease for at least 3 years or prostate cancer who is not currently or expected, during the study, to undergo radiation therapy, chemotherapy, and/or surgical intervention, or to initiate hormonal treatment.

    Exception: subjects with history of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ are eligible for enrollment.

    27. Cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, central nervous system or psychiatric disease that, in the opinion of the investigator, may adversely affect the safety of the subject and/or efficacy of the investigational product or severely limit the lifespan of the subject other than the condition being studied.

    28. Clinically significant hyperthyroidism or hypothyroidism not adequately treated.

    29. Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non- compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures).

    30. Known hypersensitivity to CXA-10, the metabolites, or formulation excipients.

    31. Treatment with any investigational drug (other than CXA-10) or device within 30 days or 5 half-lives (whichever is longer) prior to Baseline (this includes investigational formulations of marketed products, inhaled and topical drugs), or plans to participate in an investigational drug or device study at any time during this study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04053543


Contacts
Layout table for location contacts
Contact: Craig Pfister, BS 484-329-8432 craig.pfister@complexarx.com
Contact: Michael T Nelson, BA 484-329-8430 mike.nelson@complexarx.com

  Show 32 Study Locations
Sponsors and Collaborators
Complexa, Inc.
Medpace, Inc.
Innovative Analytics
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Investigators
Layout table for investigator information
Study Director: Theo Danoff, MD Complexa, Inc.

Layout table for additonal information
Responsible Party: Complexa, Inc.
ClinicalTrials.gov Identifier: NCT04053543     History of Changes
Other Study ID Numbers: CXA-10-2302
First Posted: August 12, 2019    Key Record Dates
Last Update Posted: November 26, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Complexa, Inc.:
Pulmonary Arterial Hypertension
Pulmonary Hypertension
PAH
Connective Tissue Disease- Associated
6 Minute Walk Test
6 Minute Walk Distance
Pulmonary Vascular Resistance
Cardiac MRI
Right Ventricular Function
Hypertension
Familial Primary Pulmonary Hypertension
Connective Tissue Diseases
Vascular Diseases
Hypertension, Pulmonary
Lung Diseases
Cardiovascular Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases